

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

AUSTRALIAN PRODUCT INFORMATION

ZEJULA (NIRAPARIB)

1 NAME OF THE MEDICINE

ZEJULA (niraparib)

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each capsule contains niraparib tosilate monohydrate equivalent to 100 mg niraparib. Excipients with known effect: Each capsule contains lactose monohydrate. Each capsule shell also contains the colouring agent tartrazine.

For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS.

3 PHARMACEUTICAL FORM

Capsule with a white body with “100 mg” printed in black ink and purple cap with “Niraparib” printed in white ink.

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

ZEJULA is indicated:

- for the maintenance treatment of adult patients with advanced high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
- as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

4.2 DOSE AND METHOD OF ADMINISTRATION

Treatment with ZEJULA should be initiated and supervised by a physician experienced in the use of anticancer medicinal products.

First-line ovarian cancer maintenance treatment

The recommended starting dose of niraparib is 200 mg (two 100 mg capsules) taken once daily. For patients who weigh ≥ 77 kg and have baseline platelet count $\geq 150,000/\mu\text{L}$, the recommended starting dose of niraparib is 300 mg (three 100 mg capsules) taken orally once daily.

Recurrent ovarian cancer maintenance treatment

The recommended starting dose is 300 mg (three 100 mg capsules) taken orally once daily.

Patients should be encouraged to take their dose at approximately the same time each day. Bedtime administration may be a potential method for managing nausea.

The capsules should be swallowed whole with water. The capsules should not be chewed or crushed. ZEJULA can be taken without regard to meals.

It is recommended that treatment should be continued until disease progression or unacceptable toxicity.

Missing dose

If patients miss a dose, they should take their next dose at its regularly scheduled time.

Dose adjustments for adverse reactions

To manage adverse reactions, consider interruption of treatment, dose reduction, or dose discontinuation. The recommended dose modifications for adverse reactions are listed in Tables 1, 2 and 3.

Table 1: Recommended dose modifications for adverse reactions		
<i>Starting dose</i>	200 mg/day	300 mg/day
First dose reduction	100 mg/day	200 mg/day
Second dose reduction	Discontinue medication	100 mg/day*

*If further dose reduction below 100 mg/day is required, discontinue ZEJULA.

Table 2: Dose modifications for non-haematologic adverse reactions	
Non-haematologic CTCAE [‡] ≥ Grade 3 adverse reaction that persists despite treatment/prophylaxis**	First occurrence: <ul style="list-style-type: none"> Withhold ZEJULA for a maximum of 28 days or until resolution of adverse reaction. Resume ZEJULA at a reduced dose per Table 1.. Second occurrence: <ul style="list-style-type: none"> Withhold ZEJULA for a maximum of 28 days or until resolution of adverse reaction. Resume ZEJULA at a reduced dose or discontinue per Table 1.
CTCAE ≥ Grade 3 treatment-related adverse reaction lasting more than 28 days while patient is administered ZEJULA 100 mg/day	<ul style="list-style-type: none"> Discontinue ZEJULA.

[‡]CTCAE=Common Terminology Criteria for Adverse Events

**Prophylaxis includes, but is not limited to, medications to prevent nausea, vomiting, diarrhoea, constipation, headache, back pain, myalgia, arthralgia, insomnia, decreased appetite, or dry mouth.

Table 3: Dose modifications for haematologic adverse reactions	
<p>Haematologic adverse reactions have been observed during treatment with Zejula especially during the initial phase of the treatment. It is therefore recommended to monitor complete blood counts (CBCs) weekly during the first month of treatment and modify the dose as needed. After the first month, it is recommended to monitor CBCs monthly and periodically after this time (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE). Based on individual laboratory values, weekly monitoring for the second month may be warranted.</p>	
<p>Haematologic adverse reaction requiring transfusion or haematopoietic growth factor support</p>	<ul style="list-style-type: none"> For patients with platelet count $\leq 10,000/\mu\text{L}$, platelet transfusion should be considered. If there are other risk factors for bleeding such as co-administration of anticoagulation or antiplatelet medicinal products, consider interrupting these products and/or transfusion at a higher platelet count. Resume ZEJULA at a reduced dose per Table 1..
<p>Platelet count $<100,000 \mu\text{L}$</p>	<p>First occurrence:</p> <ul style="list-style-type: none"> Withhold ZEJULA for a maximum of 28 days and monitor blood counts weekly until platelet counts return to $\geq 100,000/\mu\text{L}$. Resume ZEJULA at same or reduced dose based on clinical evaluation. If platelet count is $< 75,000/\mu\text{L}$ at any time, resume at a reduced dose per Table 1
	<p>Second occurrence:</p> <ul style="list-style-type: none"> Withhold ZEJULA for a maximum of 28 days and monitor blood counts weekly until platelet counts return to $\geq 100,000/\mu\text{L}$. Resume ZEJULA at a reduced dose per Table 1.. Discontinue ZEJULA if the platelet count has not returned to acceptable levels within 28 days of the dose interruption period, or if the patient has already undergone dose reduction to 100 mg once daily.
<p>Neutrophil $< 1,000/\mu\text{L}$ or Haemoglobin $< 8 \text{ g/dL}$</p>	<ul style="list-style-type: none"> Withhold ZEJULA for a maximum of 28 days and monitor blood counts weekly until neutrophil counts return to $\geq 1,500/\mu\text{L}$ or haemoglobin returns to $\geq 9 \text{ g/dL}$. Resume ZEJULA at a reduced dose per Table 1. Discontinue ZEJULA if neutrophils and/or haemoglobin have not returned to acceptable levels within 28 days of the dose interruption period, or if the patient has already undergone dose reduction to 100 mg once daily.
<p>Confirmed diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML)</p>	<ul style="list-style-type: none"> Permanently discontinue ZEJULA.

Elderly

No dose adjustment is necessary for elderly patients (≥ 65 years). There are limited clinical data in patients aged 75 or over.

Renal impairment

No dose adjustment is necessary for patients with mild to moderate renal impairment. There are no data in patients with severe renal impairment or end stage renal disease undergoing haemodialysis; use with caution in these patients, see Section 5.2 PHARMACOKINETIC PROPERTIES.

Hepatic impairment

No dose adjustment is needed in patients with mild to moderate hepatic impairment. There are no data in patients with severe hepatic impairment; use with caution in these patients, see Section 5.2 PHARMACOKINETIC PROPERTIES.

Patients with ECOG performance status 2 to 4

Clinical data are not available in patients with ECOG performance status 2 to 4.

Paediatric population

The safety and efficacy of ZEJULA in children and adolescents below 18 years of age have not yet been established. No data are available.

4.3 CONTRAINDICATIONS

Hypersensitivity to the active substance or to any of the excipients listed in Section 6.1 LIST OF EXCIPIENTS.

Breast-feeding (see Section 4.6 FERTILITY, PREGNANCY AND LACTATION).

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Haematologic adverse reactions

In the PRIMA study, patients eligible for ZEJULA therapy had the following baseline haematological parameters: absolute neutrophil count (ANC) $\geq 1,500$ cells/ μL ; platelets $\geq 100,000$ cells/ μL and haemoglobin ≥ 10 g/dL prior to therapy. The overall incidence of Grade ≥ 3 thrombocytopenia, anaemia and neutropenia in clinical and/or laboratory findings were reported, respectively, in 39%, 31%, and 21% of patients receiving ZEJULA. Discontinuation due to thrombocytopenia, anaemia, and neutropenia occurred, respectively, in 4%, 2%, and 2% of patients.

In patients who were administered a starting dose of ZEJULA based on baseline weight or platelet count, Grade ≥ 3 thrombocytopenia, anaemia and neutropenia were reported, respectively, in 15%, 23%, and 10% of patients receiving niraparib. Discontinuation due to thrombocytopenia, anaemia, and neutropenia occurred, respectively, in 3%, 3%, and 2% of patients.

In the NOVA study, patients eligible for ZEJULA therapy had the following baseline haematologic parameters: absolute neutrophil count (ANC) $\geq 1,500$ cells/ μL ; platelets $\geq 100,000$ / μL and haemoglobin ≥ 9 g/dL prior to therapy. Haematologic adverse reactions (thrombocytopenia, anaemia, neutropenia) have been reported in patients treated with ZEJULA. In the NOVA study, 48 of 367 (13%) of patients experienced bleeding with concurrent thrombocytopenia; all bleeding events concurrent with thrombocytopenia were Grade 1 or 2 in severity except for one event of Grade 3 petechiae and haematoma observed concurrently with a serious adverse event of pancytopenia. Thrombocytopenia

occurred more commonly in patients whose baseline platelet count was less than 180,000 cells/ μ L. Approximately 76% of patients with lower baseline platelets (< 180,000 cells/ μ L) who received ZEJULA experienced thrombocytopenia of any grade, and 45% of the patients experienced Grade 3/4 thrombocytopenia. Pancytopenia has been observed in < 1% of patients receiving ZEJULA. If a patient develops severe persistent haematologic toxicity including pancytopenia that does not resolve within 28 days following interruption, ZEJULA should be discontinued.

Grade \geq 3 thrombocytopenia, anaemia and neutropenia were reported, respectively, in 29%, 25%, and 20% of patients receiving ZEJULA. Discontinuation due to thrombocytopenia, anaemia, and neutropenia occurred, respectively, in 3%, 1%, and 2% of patients. Test complete blood counts weekly for the first month, followed by monthly monitoring for the next 10 months of treatment and periodically after this time to monitor for clinically significant changes in any haematologic parameter during treatment, see Section 4.2 DOSE AND METHOD OF ADMINISTRATION.

If a patient develops severe persistent haematological toxicity including pancytopenia that does not resolve within 28 days following interruption, ZEJULA should be discontinued. Due to the risk of thrombocytopenia, anticoagulants and medicinal products known to reduce the thrombocyte count should be used with caution, see Section 4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS).

Myelodysplastic syndrome/acute myeloid leukaemia

Myelodysplastic syndrome/acute myeloid leukaemia (MDS/AML), including cases with fatal outcome, have been reported in patients who received ZEJULA monotherapy in clinical trials. In 1785 patients treated with ZEJULA in clinical trials, MDS/AML occurred in 15 patients.

The duration of ZEJULA treatment in patients prior to developing MDS/AML varied from 1 month to > 4 years. The cases were typical of secondary, cancer therapy-related MDS/AML. All patients had received multiple platinum-containing chemotherapy regimens and many had also received other DNA damaging agents and radiotherapy. Some of the patients had a history of bone marrow dysplasia.

If MDS and/or AML are confirmed while on treatment with ZEJULA, treatment should be discontinued and the patient treated appropriately.

Hypertension, including hypertensive crisis

Hypertension, including hypertensive crisis, has been reported with the use of ZEJULA. Pre-existing hypertension should be adequately controlled before starting ZEJULA treatment. Blood pressure and heart rate should be monitored at least weekly for the first two months, then monthly for the first year and periodically thereafter during treatment with ZEJULA.

Hypertension should be medically managed with antihypertensive medicinal products as well as adjustment of the ZEJULA dose (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION), if necessary. In the clinical programme, blood pressure measurements were obtained on Day 1 of each 28-day cycle while the patient remained on ZEJULA. In most cases, hypertension was controlled adequately using standard antihypertensive treatment with or without ZEJULA dose adjustment, see Section 4.2 DOSE AND METHOD OF ADMINISTRATION. ZEJULA should be discontinued in case of hypertensive crisis or if medically significant hypertension cannot be adequately controlled with antihypertensive therapy.

Posterior Reversible Encephalopathy Syndrome (PRES)

There have been rare reports (0.09% of clinical trial patients) of niraparib-treated patients developing signs and symptoms that are consistent with Posterior Reversible Encephalopathy Syndrome (PRES) (see Section 4.8 ADVERSE REACTIONS). PRES is a rare neurologic disorder that can present with the following signs and symptoms including seizures, headache, altered mental status, visual disturbance, or cortical blindness, with or without associated hypertension. A diagnosis of PRES requires

confirmation by brain imaging, preferably magnetic resonance imaging (MRI). In patients developing PRES, treatment of specific symptoms including control of hypertension is recommended, along with discontinuation of niraparib. The safety of reinitiating niraparib therapy in patients previously experiencing PRES is not known.

Pregnancy/contraception

ZEJULA should not be used during pregnancy or in women of childbearing potential not willing to use reliable contraception during therapy and for 1 month after receiving the last dose of ZEJULA (see Section 4.6 FERTILITY, PREGNANCY AND LACTATION). A pregnancy test should be performed on all women of childbearing potential prior to treatment.

Lactose

ZEJULA capsules contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Tartrazine

This medicinal product contains tartrazine, which may cause allergic reactions.

Use in the elderly

See Section 4.2 DOSE AND METHOD OF ADMINISTRATION.

Paediatric use

See Section 4.2 DOSE AND METHOD OF ADMINISTRATION.

Effects on laboratory tests

No data available.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Pharmacodynamic interactions

The combination of ZEJULA with vaccines or immunosuppressant agents has not been studied.

The data on ZEJULA in combination with cytotoxic medicinal products are limited. Therefore, caution should be taken if ZEJULA is used in combination with vaccines, immunosuppressant agents or with other cytotoxic medicinal products.

Pharmacokinetic interactions

Effect of other medicinal products on niraparib

Niraparib as a substrate of CYPs (CYP1A2 and CYP3A4)

Niraparib is a substrate of carboxylesterases (CEs) and UDP-glucuronosyltransferases (UGTs) *in vivo*. Oxidative metabolism of niraparib is minimal *in vivo*. No dose adjustment for ZEJULA is required when administered concomitantly with medicinal products known to inhibit (e.g. itraconazole, ritonavir, and clarithromycin) or induce CYP enzymes (e.g. rifampin, carbamazepine, and phenytoin).

Niraparib as a substrate of efflux transporters (P-gp, BCRP, and MATE1/2)

Niraparib is a substrate of P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). However, due to its high permeability and bioavailability, the risk of clinically relevant interactions with

medicinal products that inhibit these transporters is unlikely. Therefore, no dose adjustment for ZEJULA is required when administered concomitantly with medicinal products known to inhibit P-gp (e.g. amiodarone, verapamil) or BCRP (e.g. osimertinib, velpatasvir, and eltrombopag).

Niraparib is not a substrate of bile salt export pump (BSEP). The major primary metabolite M1 is not a substrate of P-gp, BCRP, or BSEP. Niraparib is not a substrate of MATE 1 or 2, while M1 is a substrate of both.

Niraparib as a substrate of hepatic uptake transporters (OATP1B1, OATP1B3, and OCT1)

Neither niraparib nor M1 is a substrate of organic anion transport polypeptide 1B1 (OATP1B1), 1B3 (OATP1B3), or organic cation transporter 1 (OCT1). No dose adjustment for ZEJULA is required when administered concomitantly with medicinal products known to inhibit OATP1B1 or 1B3 (e.g. gemfibrozil, ritonavir), or OCT1 (e.g. dolutegravir) uptake transporters.

Niraparib as a substrate of renal uptake transporters (OAT1, OAT3, and OCT2)

Neither niraparib nor M1 is a substrate of organic anion transporter 1 (OAT1), 3 (OAT3), and organic cation transporter 2 (OCT2). No dose adjustment for ZEJULA is required when administered concomitantly with medicinal products known to inhibit OAT1 (e.g. probenecid) or OAT3 (e.g. probenecid, diclofenac), or OCT2 (e.g. cimetidine, quinidine) uptake transporters.

Effect of niraparib on other medicinal products

Inhibition of CYPs (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4)

Neither niraparib nor M1 is an inhibitor of any active substance-metabolising CYP enzymes, namely CYP1A1/2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5.

Even though inhibition of CYP3A4 in the liver is not expected, the potential to inhibit CYP3A4 at the intestinal level has not been established at relevant niraparib concentrations. Therefore, caution is recommended when niraparib is combined with active substances the metabolism of which is CYP3A4-dependent and, notably, those having a narrow therapeutic range (e.g. ciclosporin, tacrolimus, alfentanil, ergotamine, pimozide, quetiapine, and halofantrine).

Induction of CYPs (CYP1A2 and CYP3A4)

Neither niraparib nor M1 is a CYP3A4 inducer *in vitro*. *In vitro*, niraparib weakly induces CYP1A2 at high concentrations and the clinical relevance of this effect cannot be completely ruled out. M1 is not a CYP1A2 inducer. Therefore, caution is recommended when niraparib is combined with active substances the metabolism of which is CYP1A2-dependent and, notably, those having a narrow therapeutic range (e.g. clozapine, theophylline, and ropinirole).

Inhibition of efflux transporters (P-gp, BCRP, BSEP, and MATE1/2)

Niraparib is not an inhibitor of BSEP. *In vitro*, niraparib inhibits P-gp very weakly and BCRP with an IC_{50} = 161 μ M and 5.8 μ M, respectively. Therefore, a clinically meaningful interaction related to an inhibition of these efflux transporters although unlikely, cannot be excluded. Caution is thus recommended when niraparib is combined with substrates of BCRP (irinotecan, rosuvastatin, simvastatin, atorvastatin, and methotrexate).

Niraparib is an inhibitor of MATE1 and -2 with IC_{50} of 0.18 μ M and \leq 0.14 μ M, respectively. Increased plasma concentrations of co-administered medicinal products that are substrates of these transporters (e.g. metformin) cannot be excluded.

The major primary metabolite M1 does not appear to be an inhibitor of P-gp, BCRP, BSEP, or MATE1/2.

Inhibition of hepatic uptake transporters (OATP1B1, OATP1B3, and OCT1)

Neither niraparib nor M1 is an inhibitor of organic anion transport polypeptide 1B1 (OATP1B1) or 1B3 (OATP1B3).

In vitro, niraparib weakly inhibits the organic cation transporter 1 (OCT1) with an $IC_{50} = 34.4 \mu\text{M}$. Caution is recommended when niraparib is combined with active substances that undergo an uptake transport by OCT1 such as metformin.

Inhibition of renal uptake transporters (OAT1, OAT3, and OCT2)

Neither niraparib nor M1 inhibits organic anion transporter 1 (OAT1), 3 (OAT3), and organic cation transporter 2 (OCT2).

All clinical studies have only been performed in adults.

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on fertility

There are no clinical data on fertility. While no direct fertility studies were conducted in animals, repeat-dose toxicity studies in rats and dogs showed decreased spermatogenesis, small testes and germ cell depletion in the testes and epididymides at niraparib doses of 20 mg/kg/day and 6 mg/kg/day (0.74- and 0.05-times clinical exposure based on AUC, respectively). There was a trend towards reversibility of these findings 2-4 weeks after dosing was stopped.

Use in pregnancy (Category D)

There are no or a limited amount of data from the use of ZEJULA in pregnant women. Animal reproductive and developmental toxicity studies have not been conducted. However, based on its mechanism of action, ZEJULA could cause embryonic or fetal harm, including embryo-lethal and teratogenic effects, when administered to a pregnant woman. ZEJULA should not be used during pregnancy.

Women of childbearing potential should not become pregnant while on treatment and should not be pregnant at the beginning of treatment. A pregnancy test should be performed on all women of childbearing potential prior to treatment. Women of childbearing potential must use effective contraception during therapy and for 1 month after receiving the last dose of ZEJULA.

Use in lactation

It is unknown whether niraparib or its metabolites are excreted in human milk. Breast-feeding is contraindicated during administration of ZEJULA and for 1 month after receiving the last dose (see Section 4.3 CONTRAINDICATIONS).

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

ZEJULA has a moderate influence on the ability to drive or use machines. Patients who take ZEJULA may experience asthenia, fatigue and dizziness. Patients who experience these symptoms should observe caution when driving or using machines.

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Tabulated list of adverse reactions

The following adverse reactions have been identified based on pooled data generated from the PRIMA and NOVA clinical trials in patients receiving ZEJULA monotherapy and during post-marketing experience (see Table 4).

Frequencies of occurrence of undesirable effects are defined as: very common $\geq 1/10$); common $\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1,000$ to $< 1/100$); rare ($\geq 1/10,000$ to $< 1/1,000$); very rare ($< 1/10,000$). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Table 4: Adverse drug reactions reported in patients treated with a fixed starting dose of 300 mg/day of niraparib (PRIMA and NOVA trial pool)

System Organ Class	Frequency of all CTCAE* grades	Frequency of CTCAE grade 3 or 4*
Infections and infestations	Very common Urinary tract infection Common Bronchitis, conjunctivitis	Uncommon Urinary tract infection, bronchitis
Blood and lymphatic system disorders	Very common Thrombocytopenia, anaemia, neutropenia, leukopenia Common Neutropenic infection Uncommon Pancytopenia, febrile neutropenia, neutropenic sepsis	Very common Thrombocytopenia, anaemia, neutropenia Common Leukopenia Uncommon Neutropenic infection, febrile neutropenia, neutropenic sepsis, pancytopenia
Metabolism and nutrition disorders	Very common Decreased appetite Common Hypokalemia	Common Hypokalemia Uncommon Decreased appetite
Psychiatric disorders	Very common Insomnia Common Anxiety, depression	Uncommon Insomnia, anxiety, depression
Nervous system disorders	Very common Headache, dizziness Common Dysgeusia Rare Posterior Reversible Encephalopathy Syndrome (PRES)**	Uncommon Headache Rare Posterior Reversible Encephalopathy Syndrome (PRES)**
Cardiac disorders	Very common Palpitations Common Tachycardia	

System Organ Class	Frequency of all CTCAE* grades	Frequency of CTCAE grade 3 or 4*
Vascular disorders	Very common Hypertension Rare Hypertensive crisis	Common Hypertension Rare Hypertensive crisis
Respiratory, thoracic and mediastinal disorders	Very common Dyspnoea, cough, nasopharyngitis Common Epistaxis	Uncommon Dyspnoea, epistaxis
Gastrointestinal disorders	Very common Nausea, constipation, vomiting, abdominal pain, diarrhoea, dyspepsia Common Dry mouth, mucositis, stomatitis	Common Nausea, vomiting, abdominal pain Uncommon Diarrhoea, constipation, mucositis, stomatitis, dry mouth
Skin and subcutaneous tissue disorders	Common Photosensitivity, rash	Uncommon Photosensitivity, rash
Musculoskeletal and connective tissue disorders	Very common Back pain, arthralgia Common Myalgia	Uncommon Back pain, arthralgia, myalgia
General disorders and administration site conditions	Very common Fatigue, asthenia Common Oedema peripheral	Common Fatigue, asthenia
Investigations	Common Gamma-glutamyl transferase increased, AST increased, blood creatinine increased, ALT increased, blood alkaline phosphatase increased, weight decreased	Common Gamma-glutamyl transferase increased, ALT increased Uncommon AST increased, blood alkaline phosphatase increased

*CTCAE=Common Terminology Criteria for Adverse Events version 4.02

** Based on ZEJULA clinical trial data. This is not limited to pivotal ENGOT-OV16 monotherapy study.

Patients Receiving ZEJULA with Dose Based on Baseline Weight or Platelet Count in PRIMA:

Results for commonly reported events for patients receiving a 300 mg fixed starting dose or a 200 – 300 mg individualised starting dose based on baseline weight or platelet count, are summarised in Table 5. Commonly reported Grade ≥3 events are summarised in Table 6.

The adverse reactions noted in the group of patients who were administered a 200-mg starting dose of niraparib based on baseline weight or platelet count were of similar or lesser frequency compared to the group administered 300 mg. See Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE for specific information regarding frequency of thrombocytopenia, anaemia and neutropenia. In general, the individualised starting dose decreased the incidence of myelosuppression events including anaemia (71% vs 50%) and thrombocytopenia (52% vs 34%) as compared to the fixed starting dose.

Table 5. Treatment Emergent Adverse Reactions Reported in ≥10% of Patients Receiving ZEJULA in PRIMA by Fixed or Individualised Starting Dose

MedDRA Preferred Term (Grade 1-4) ^c	Fixed ^a		Individualised ^b	
	ZEJULA (n = 315) %	Placebo (n = 158) %	ZEJULA (n = 169) %	Placebo (n = 86) %
Blood and lymphatic system disorders				
Thrombocytopenia	52	4	34	4
Anaemia	71	12	50	28
Neutropenia ^d	28	6	24	7
Leukopenia ^e	12	5	12	6
Gastrointestinal disorders				
Nausea	60	31	53	21
Constipation	43	21	31	15
Vomiting	25	13	17	9
General disorders and administration site conditions				
Fatigue	36	29	33	30
Metabolism and nutrition disorders				
Decreased appetite	19	10	19	5
Musculoskeletal and connective tissue disorders				
Arthralgia	18	18	17	21
Back Pain	15	10	10	11
Nervous system disorders				
Headache	28	13	22	17
Dizziness	17	11	11	11
Psychiatric disorders				
Insomnia	27	15	21	14

Respiratory, thoracic, and mediastinal disorders				
Dyspnea	19	13	16	11
Cough	15	14	0	0.4
Vascular disorders				
Hypertension	18	6	16	9
Investigations				
AST increased	10	4	7	5

MedDRA= Medical Dictionary for Regulatory Activities; AST = aspartate aminotransferase

^a Patients received a fixed starting dose of 300 mg prior to PRIMA protocol amendment.

^b Individualised starting dose: 200 mg in patients with body weight <77 kg or platelet count <150,000/ μ L or 300 mg in patients with body weight \geq 77 kg and platelet count \geq 150,000/ μ L.

^c All TEAEs in the table consist of grouped preferred terms except for nausea, vomiting, decreased appetite, headache, and insomnia, which are single preferred terms.

^d Includes neutropenia, neutropenic infection, neutropenic sepsis, and febrile neutropenia.

^e Includes leukopenia, lymphocyte count decreased, lymphopenia, and white blood cell count decreased.

Table 6. Grade 3 or 4 Treatment Emergent Adverse Reactions Reported in \geq 5% of Patients Receiving ZEPJULA in PRIMA by Fixed or Individualised Starting Dose

MedDRA Preferred Term (Grade 3-4) ^c	Fixed ^a		Individualised ^b	
	ZEPJULA (n = 315) %	Placebo (n = 158) %	ZEPJULA (n = 169) %	Placebo (n = 86) %
Blood and lymphatic system disorders				
Thrombocytopenia	36	0	15	1
Anaemia	36	2	23	1
Platelet count decreased	16	0	7	0
Neutropenia ^d	15	1	10	1
Neutrophil count decreased	9	0	5	0
Vascular disorders				
Hypertension	6	1	5	2

MedDRA= Medical Dictionary for Regulatory Activities; AST = aspartate aminotransferase

^a Patients received a fixed starting dose of 300 mg prior to PRIMA protocol amendment.

^b Individualised starting dose: 200 mg in patients with body weight <77 kg or platelet count <150,000/ μ L or 300 mg in patients with body weight \geq 77 kg and platelet count \geq 150,000/ μ L.

^c All TEAEs in the table consist of grouped preferred terms except for nausea, vomiting, decreased appetite, headache, and insomnia, which are single preferred terms.

^d Includes neutropenia, neutropenic infection, neutropenic sepsis, and febrile neutropenia.

Post-marketing data

In addition to the adverse reactions identified from clinical trial data, the adverse reactions presented in Table 7 have been identified in post-approval use of ZEJULA.

Table 7 Adverse reactions identified from post-marketing data

Immune system disorders hypersensitivity (including anaphylaxis)
Psychiatric disorders confusional state/disorientation, hallucination, cognitive impairment (e.g., memory impairment, concentration impairment)
Respiratory, thoracic, and mediastinal disorders non-infectious pneumonitis

Description of selected adverse reactions

Haematologic adverse reactions (thrombocytopenia, anaemia, neutropenia), including clinical diagnoses and/or laboratory findings generally occurred early during ZEJULA treatment with the incidence decreasing over time.

In the clinical programme, haematological adverse reactions were managed with laboratory monitoring and dose modifications (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION).

Thrombocytopenia

In the PRIMA safety population (n = 484), 39% of ZEJULA-treated patients experienced Grade 3-4 thrombocytopenia compared to 0.4% of placebo-treated patients with a median time from first dose to first onset in the ZEJULA arm of 22 days (range: 15 to 335 days) and with a median duration of 6 days (range: 1 to 374 days). Discontinuation due to thrombocytopenia occurred in 4% of patients.

In NOVA, approximately 60% of patients receiving ZEJULA experienced thrombocytopenia of any grade, and 34% of patients experienced Grade 3/4 thrombocytopenia. In patients with baseline platelet count less than 180,000 cells/ μ L, thrombocytopenia of any grade and Grade 3/4 occurred in 76% and 45% of the patients, respectively. The median time to onset of thrombocytopenia regardless of grade, and Grade 3/4 thrombocytopenia was 22 and 23 days, respectively. The rate of new incidences of thrombocytopenia after intensive dose modifications were performed during the first two months of treatment from Cycle 4 was 1.2%. The median duration of thrombocytopenia events of any grade was 23 days, and the median duration of Grade 3/4 thrombocytopenia was 10 days. Patients treated with ZEJULA who develop thrombocytopenia might have an increased risk of haemorrhage. Discontinuation due to thrombocytopenia events (thrombocytopenia and platelet count decreased) occurred in approximately 3% of the patients.

Anaemia

In the PRIMA safety population (n = 484), 31% of niraparib-treated patients experienced Grade 3/4 anaemia compared to 2% of placebo-treated patients with a median time from first dose to first onset in

the niraparib arm of 80 days (range: 15 to 533 days) and with a median duration of 7 days (range: 1 to 119 days). Discontinuation due to anaemia occurred in 2% of patients.

In NOVA, approximately 50% of patients experienced anaemia of any grade, and 25% experienced Grade 3/4 anaemia. The median time to onset of anaemia of any grade was 42 days, and 85 days for Grade 3/4 events. The median duration of anaemia of any grade was 63 days, and 8 days for Grade 3/4 events. Anaemia of any grade might persist during ZEJULA treatment. In the clinical programme, anaemia was managed with laboratory monitoring, dose modification (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION), and, where appropriate, with red blood cell transfusions. Discontinuation due to anaemia occurred in 1% of patients.

Neutropenia

In the PRIMA safety population (n = 484), 21% of niraparib-treated patients experienced Grade 3-4 neutropenia compared to 1% of placebo-treated patients with a median time from first dose to first onset in the ZEJULA arm of 29 days (range: 15 to 421 days) and with a median duration of 8 days (range: 1 to 42 days). Discontinuation due to neutropenia occurred in 2% of patients.

In NOVA, approximately 30% of patients receiving ZEJULA experienced neutropenia of any grade, and 20% of patients experienced Grade 3/4 neutropenia. The median time to onset of neutropenia of any grade was 27 days, and 29 days for Grade 3/4 events. The median duration of neutropenia of any grade was 26 days, and 13 days for Grade 3/4 events. In the clinical programme, neutropenia was managed with laboratory monitoring and dose modifications (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION). In addition, Granulocyte-Colony Stimulating Factor (G-CSF) was administered to approximately 6% of patients treated with ZEJULA as concomitant therapy for neutropenia. Discontinuation due to neutropenia events occurred in 2% of patients.

Hypertension

In the PRIMA safety population (n = 484), Grade 3-4 hypertension occurred in 6% of ZEJULA-treated patients compared to 1% of placebo-treated patients with a median time from first dose to first onset in the ZEJULA arm of 50 days (range: 1 to 589 days) and with a median duration of 12 days (range: 1 to 61 days). Discontinuation due to hypertension occurred in 0% of patients.

Hypertension, including hypertensive crisis, has been reported with ZEJULA therapy. In NOVA, hypertension of any grade occurred in 19.3% of patients treated with ZEJULA. Grade 3/4 hypertension occurred in 8.2% of patients. Discontinuation due to hypertension occurred in < 1% of patients.

Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 OVERDOSE

There is no specific treatment in the event of ZEJULA overdose, and symptoms of overdose are not established. In the event of an overdose, physicians should provide general supportive measures and should treat symptomatically.

For information on the management of overdose, contact the Poison Information Centre on 131126 (Australia).

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Mechanism of action

Niraparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP-1 and PARP-2, which play a role in DNA repair. In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis and cell death. Increased niraparib-induced cytotoxicity was observed in tumour cell lines with or without deficiencies in the BRCA1 and 2 tumour suppressor genes. In orthotopic high-grade serous ovarian cancer patient derived xenograft tumours (PDX) grown in mice, niraparib has been shown to reduce tumour growth in BRCA1 and 2 mutant, BRCA wild-type but homologous recombination (HR) deficient, and in tumours that are BRCA wild-type and without detectable HR deficiency.

Clinical trials

First-line ovarian cancer maintenance treatment

PRIMA was a double-blind, placebo-controlled trial in which patients (n=733) in complete or partial response to first-line platinum-based chemotherapy were randomised 2:1 to ZEJULA or matched placebo.

Patients were randomised post-completion of first-line platinum-based chemotherapy plus/minus surgery. Bevacizumab was allowed with chemotherapy. Patients who had neoadjuvant chemotherapy followed by interval debulking surgery could have visible residual or no residual disease. Randomisation was stratified by best response during the front-line platinum regimen (complete response vs partial response), neoadjuvant chemotherapy (NACT) (Yes vs No), and homologous recombination deficiency (HR) status [positive vs negative or not determined]. Testing for HRD was performed using the HRD test on tumour tissue obtained at the time of initial diagnosis.

PRIMA was initiated with a starting dose of 300 mg once daily in continuous 28-day cycles (henceforth referred to as a fixed starting dose or FSD). Based on retrospective analyses of the NOVA trial, the starting dose in PRIMA was changed with Amendment 2 of the Protocol. From that point forward, patients with a baseline body weight ≥ 77 kg and baseline platelet count $\geq 150,000/\mu\text{L}$ were administered niraparib 300 mg (3x100 mg capsules) or placebo (3 capsules) daily and patients with a baseline body weight < 77 kg or baseline platelet count $< 150,000/\mu\text{L}$ were administered ZEJULA 200 mg (2x100 mg capsules) or placebo (2 capsules) daily (henceforth referred to as an individualised starting dose or ISD).

Patients began treatment on Cycle 1/Day 1 (C1/D1) with ZEJULA 200 or 300 mg or matched placebo administered once daily in continuous 28-day cycles. In the PRIMA study, 52 % of patients had a dose interruption in Cycle 1, 9% of patients in Cycle 1 and 47% of patients in Cycle 2 had a dose reduction.

Overall, the median dose intensity in subjects who received ZEJULA was 181.3 mg/day and the median relative dose intensity was 63% in subjects who received ZEJULA. In patients who received the individualised starting dose, the median dose intensity was 178.6 mg/day and the median relative dose intensity was 66%. In patients who received the fixed starting dose, the median dose intensity was 181.8 mg/day and the median relative dose intensity was 61%.

The major efficacy outcome measure, progression-free survival (PFS), was determined by blinded independent central review (BICR) per RECIST, version 1.1. Overall survival (OS) was a key secondary

objective. PFS testing was performed hierarchically: first in the HR deficient population, then in the overall population.

The median age was 62 and ranged from 32 to 85 years among patients randomised to ZEJULA and 33 to 88 years among patients randomised to placebo. Eighty-nine percent of all patients were white. Sixty-nine percent of patients randomised with niraparib and 71% of patients randomised with placebo had an ECOG of 0 at study baseline. In the overall population, 65% of patients had stage III disease, 35% had stage IV disease and the proportions of patients by primary tumour were as follows: ovarian (80.4%), primary peritoneal (6.4%) and fallopian (13.2%). Sixty-seven percent of the patients received NACT. Sixty-nine percent of the patients had a complete response to the first-line platinum-based chemotherapy.

In the PRIMA study bevacizumab was received by 6 (1.2%) patients in niraparib arm and 1 (0.4) in placebo group. Subjects who had received bevacizumab with their first-line platinum-based therapy but were unable to receive bevacizumab as maintenance therapy due to AEs or for any other reason, were deemed eligible to enter the PRIMA study.

PRIMA demonstrated a statistically significant improvement in PFS for patients randomised to ZEJULA as compared with placebo in the HR deficient and overall population (Table 8 and Figures 1 and 2).

Table 8: Efficacy results – PRIMA (determined by BICR^a)

	HR deficient population		Overall population	
	ZEJULA (N=247)	placebo (N=126)	niraparib (N=487)	placebo (N=246)
PFS median (months; 95% CI) ^b	21.9 (19.3, NE)	10.4 (8.1, 12.1)	13.8 (11.5, 14.9)	8.2 (7.3, 8.5)
p-value ^b	<0.0001		<0.0001	
Hazard ratio (HR) ^c (95% CI)	0.43 (0.31, 0.59)		0.62 (0.50, 0.76)	

^a efficacy analysis was based on blinded independent central review (BICR).

^b based on a stratified log-rank test

^c based on a stratified Cox proportional hazards model

NE=Not Evaluable

In patients who were administered 200 or 300 mg dose of ZEJULA based on baseline weight or platelet count, comparable efficacy was observed with a hazard ratio of 0.39 (95% CI [0.22, 0.72]) in the HR deficient population, and with a hazard ratio of 0.69 (95% CI [0.48, 0.98]) in the overall population. Efficacy in this individualised dosing regimen was also maintained in the HRp population with hazard ratio of 0.70 (95% CI [0.40 to 1.23]).

Figure 1: Progression-free survival in patients with HR deficient tumours (ITT population, N=373)





Figure 2: Progression-free survival in the overall population (ITT population, N=733)



Within the HR deficient population, a hazard ratio of 0.40 (95% CI [0.27, 0.62]) was observed in the subgroup of patients with *BRCAMut* ovarian cancer (N = 223). In the subgroup of patients without a *BRCA* mutation (N = 150), a hazard ratio of 0.50 (95% CI [0.31, 0.83]) was observed. In the HR proficient

(HRD negative) population (N= 249), a hazard ratio of 0.68 (95% CI [0.49, 0.94]) was observed.

At the time of the PFS analysis, overall survival data were immature.

No statistically significant differences were observed between ZEJULA and placebo in patient reported symptoms or HRQoL as measured by improvement and worsening rates in FOSI, EQ-5D-5L, and EORTC-QLQ.

Recurrent ovarian cancer maintenance treatment

The safety and efficacy of ZEJULA as maintenance therapy was studied in a Phase 3 randomised, double-blind, placebo-controlled international trial (NOVA) in patients with relapsed predominantly high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who were platinum sensitive, defined by complete response (CR) or partial response (PR) for more than six months to their penultimate (next to last) platinum-based therapy. To be eligible for ZEJULA treatment, the patient was required to be in response (CR or PR) following completion of last platinum-based chemotherapy. The CA-125 levels were required to be normal (or a > 90% decrease in CA-125 from baseline) following their last platinum treatment and be stable for at least 7 days. Patients should not have received prior PARP inhibitor therapy, including ZEJULA. Eligible patients were assigned to one of two cohorts based on the results of a germline *BRCA* mutation test. Within each cohort, patients were randomised using a 2:1 allocation of ZEJULA and placebo. Patients were assigned to the *gBRCA*mut cohort based on blood samples for *gBRCA* analysis that were taken prior to randomisation. Testing for *gBRCA* mutation and HRD was performed using the HRD test on tumour tissue obtained at the time of initial diagnosis or at the time of recurrence.

Randomisation within each cohort was stratified by time to progression after the penultimate platinum therapy before study enrolment (6 to < 12 months and ≥ 12 months); use or not of bevacizumab in conjunction with the penultimate or last platinum regimen; and best response during the most recent platinum regimen (complete response and partial response).

Patients began treatment on Cycle 1/Day 1 (C1/D1) with ZEJULA 300 mg or matched placebo administered QD in continuous 28-day cycles. Clinic visits occurred each cycle (4 weeks ± 3 days).

In the NOVA study, 48% of patients had a dose interruption in Cycle 1. Approximately 47% of patients restarted at a reduced dose in Cycle 2.

The most commonly used dose in ZEJULA-treated patients in the NOVA study was 200 mg.

Progression-free survival was determined per RECIST (Response Evaluation Criteria in Solid Tumors, version 1.1) or clinical signs and symptoms and increased CA-125. PFS was measured from the time of randomisation (which occurred up to 8 weeks after completion of the chemotherapy regimen) to disease progression or death.

The primary efficacy analysis for PFS was determined by blinded central independent assessment and was prospectively defined and assessed for the *gBRCA*mut cohort and the non-*gBRCA*mut cohort separately.

Secondary efficacy endpoints included chemotherapy-free interval (CFI), time to first subsequent therapy (TFST), PFS after the first subsequent therapy (PFS2), time to second subsequent therapy (TSST) and OS (overall survival).

Demographics, baseline disease characteristics, and prior treatment history were generally well balanced between the ZEJULA and placebo arms in the *gBRCA*mut (n = 203) and the non-*gBRCA*mut cohorts (n = 350). Median ages ranged from 57 to 63 years across treatments and cohorts. The primary

tumour site in most patients (> 80%) within each cohort was the ovary; most patients (> 84%) had tumours with serous histology. A high proportion of patients in both treatment arms in both cohorts had received 3 or more prior lines of chemotherapy, including 49% and 34% of ZEJULA patients in the *gBRCAmut* and non-*gBRCAmut* cohorts, respectively. Most patients were age 18 to 64 years (78%), Caucasian (86%) and had an ECOG performance status of 0 (68%).

In the *gBRCAmut* cohort, the median number of treatment cycles was higher in the ZEJULA arm than the placebo arm (14 and 7 cycles, respectively). More patients in the ZEJULA group continued treatment for more than 12 months than patients in the placebo group (54.4% and 16.9% respectively).

In the overall non-*gBRCAmut* cohort, the median number of treatment cycles was higher in the ZEJULA arm than in the placebo arm (8 and 5 cycles, respectively). More patients in the ZEJULA group continued treatment for more than 12 months than patients in the placebo group (34.2% and 21.1%, respectively).

The study met its primary objective of statistically significantly improved PFS for ZEJULA maintenance monotherapy compared with placebo in the *gBRCAmut* cohort (HR 0.27; 95% CI* 0.173, 0.410; $p < 0.0001$) as well as in the overall non-*gBRCAmut* cohort (HR 0.45; 95% CI* 0.338, 0.607; $p < 0.0001$). Table 9 shows the results for the PFS primary endpoint for the primary efficacy populations (*gBRCAmut* cohort and the overall non-*gBRCAmut* cohort).

Table 9: Summary of primary objective outcomes in the ENGOT-OV16 study

	<i>gBRCAmut</i> cohort		Non- <i>gBRCAmut</i> cohort	
	ZEJULA (N = 138)	placebo (N = 65)	ZEJULA (N = 234)	placebo (N = 116)
PFS median in months (95% CI*)	21.0 (12.9, NR)	5.5 (3.8, 7.2)	9.3 (7.2, 11.2)	3.9 (3.7, 5.5)
p-value	< 0.0001		< 0.0001	
Hazard ratio (HR) (Nir:plac) (95% CI*)	0.27 (0.173, 0.410)		0.45 (0.338, 0.607)	

* CI denotes confidence interval.

Prior to unblinding of the study, tumours of patients were tested for the presence of HRD using an experimental HRD test, which evaluates three indirect measures of tumour genome instability: loss of heterozygosity, telomeric allelic imbalance (TAI), and large-scale state transitions. In the HRDpos group, the hazard ratio was 0.38 (95% CI, 0.243, 0.586; $p < 0.0001$). In the HRDneg group, the hazard ratio was 0.58 (95% CI, 0.361, 0.922; $p = 0.0226$). The experimental test was not able to discriminate which patients would or would not benefit from ZEJULA maintenance therapy.

Figure 3: Kaplan-Meier plot for progression-free survival in the gBRCAmut cohort based on IRC assessment (ITT population, N = 203)





Figure 4: Kaplan-Meier plot for progression-free survival in the non-gBRCAmut cohort overall based on IRC assessment (ITT population, N = 350)



The secondary endpoints CFI, TFST, and PFS2 demonstrated a statistically significant and persistent treatment effect in favour of the ZEJULA treatment arm in the gBRCAmut cohort and the overall non-gBRCAmut cohort (Table 10).

Table 10: Secondary endpoints*

Endpoint	gBRCAmut		non-gBRCAmut	
	ZEJULA N = 138	Placebo N = 65	ZEJULA N= 234	Placebo N = 116
Chemotherapy-free interval				
Median (95% CI) – months	22.8 (17.9-NR)	9.4 (7.9-10.6)	12.7 (11.0-14.7)	8.6 (6.9-10.0)
P value	< 0.001		< 0.001	
Hazard ratio (95% CI)	0.26 (0.17-0.41)		0.50 (0.37-0.67)	
Time to first subsequent treatment				
Median (95% CI) – months	21.0 (17.5-NR)	8.4 (6.6-10.6)	11.8 (9.7-13.1)	7.2 (5.7-8.5)
P value	< 0.001		< 0.001	
Hazard ratio (95% CI)	0.31 (0.21-0.48)		0.55 (0.41-0.72)	
Progression-free survival 2				
Median (95% CI) – months	25.8 (20.3-NR)	19.5 (13.3-NR)	18.6 (16.2-21.7)	15.6 (13.2-20.9)
P value	0.006		0.03	
Hazard ratio (95% CI)	0.48 (0.28-0.82)		0.69 (0.49-0.96)	

*CI denotes confidence interval, gBRCAmut germline BRCA mutation, and NR not reached

Patient-reported outcome (PRO) data from validated survey tools (FOSI and EQ-5D) indicate that ZEJULA-treated patients reported no difference from placebo in measures associated with quality of life (QoL).

At the time of the PFS analysis, limited overall survival data were available with 17% deaths across the two cohorts.

5.2 PHARMACOKINETIC PROPERTIES

Absorption

Following a single-dose administration of 300 mg niraparib under fasting conditions, niraparib was measurable in plasma within 30 minutes and the mean peak plasma concentration (C_{max}) for niraparib was reached in about 3 hours [804 ng/mL (% CV:50.2%)]. Following multiple oral doses of niraparib from 30 mg to 400 mg once daily, accumulation of niraparib was approximately 2 to 3 folds.

The systemic exposures (C_{max} and AUC) to niraparib increased in a dose-proportional manner when the dose of niraparib increased from 30 mg to 400 mg. The absolute bioavailability of niraparib is approximately 73%, indicating minimal first pass effect.

Administration of ZEJULA (3 x 100 mg) with a high-fat high-calorie meal may result in a slight decrease in C_{max} (~20%) relative to administration of ZEJULA (3 x 100 mg) under fasted conditions. Food did not significantly affect the overall exposure of niraparib (AUC_T and AUC_{∞}).

Distribution

Niraparib was moderately protein bound in human plasma (83.0%), mainly with serum albumin. In a population pharmacokinetic analysis of niraparib, the Vd/F was 1,074 L in cancer patients, indicating extensive tissue distribution of niraparib.

Metabolism

Niraparib is metabolised primarily by carboxylesterases (CEs) to form a major inactive metabolite, M1. In a mass balance study, M1 and M10 (the subsequently formed M1 glucuronides) were the major circulating metabolites.

Excretion

Following a single oral 300-mg dose of niraparib, the mean terminal half-life ($t_{1/2}$) of niraparib ranged from 48 to 51 hours (approximately 2 days). In a population pharmacokinetic analysis, the apparent total clearance (CL/F) of niraparib was 16.2 L/h in cancer patients.

Niraparib is eliminated primarily through the hepatobiliary and renal routes. Following an oral administration of a single 300-mg dose of [¹⁴C]-niraparib, on average 86.2% (range 71% to 91%) of the dose was recovered in urine and faeces over 21 days. Radioactive recovery in the urine accounted for 47.5% (range 33.4% to 60.2%) and in the faeces for 38.8% (range 28.3% to 47.0%) of the dose. In pooled samples collected over 6 days, 40.0% of the dose was recovered in the urine primarily as metabolites and 31.6% of the dose was recovered in the faeces primarily as unchanged niraparib.

Special populations

Renal impairment

In the population pharmacokinetic analysis of data from clinical studies in patients, pre-existing mild (CLCr < 90 - ≥ 60 ml/min) and moderate (CLCr < 60 - ≥ 30 mL/min) renal impairment did not influence the clearance of niraparib. No patients with pre-existing severe renal impairment or end-stage renal disease undergoing hemodialysis were identified in clinical studies (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION).

Hepatic impairment

In the population pharmacokinetic analysis of data from clinical studies in patients, pre-existing mild and moderate hepatic impairment did not influence the clearance of niraparib. The pharmacokinetics of niraparib have not been assessed in patients with severe hepatic impairment (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION).

Age, weight and race

Population pharmacokinetic analyses indicated that age, weight and race had no significant impact on the pharmacokinetics of niraparib.

Paediatric population

No studies have been conducted to investigate the pharmacokinetics of niraparib in paediatric patients.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity

Niraparib was not mutagenic in a bacterial reverse mutation assay (Ames) test but was clastogenic in an in vitro mammalian chromosomal aberration assay and in an *in vivo* rat bone marrow micronucleus

assay. This clastogenicity is consistent with genomic instability resulting from the primary pharmacology of niraparib and indicates potential for genotoxicity in humans.

Carcinogenicity

Carcinogenicity studies have not been conducted with niraparib.

Animal pharmacology and toxicology

In vitro, niraparib inhibited dopamine (DAT) and norepinephrine (NET) transporters at concentration levels below anticipated human exposure levels (based on unbound C_{max}). In mice, single doses of niraparib increased intracellular levels of dopamine and metabolites in the cortex. Reduced locomotor activity was seen in one of two single dose studies in mice. The clinical relevance of these findings is not known but effects on blood pressure and pulse rate that may be related to inhibition of these transporters have occurred in patients.

In repeat-dose oral toxicity studies, niraparib was administered daily for up to 3 months' duration in rats and dogs. The major primary target organ for toxicity in both species was the bone marrow, with associated changes in peripheral haematology parameters. Additionally, decreased spermatogenesis was seen in both species. These findings occurred at exposure levels below those seen clinically, and were largely reversible within 4 weeks of cessation of dosing in dogs but not rats.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

Capsule content:

lactose monohydrate, magnesium stearate

Capsule shell:

titanium dioxide, gelatin, brilliant blue FCF, erythrosine, tartrazine

Printing inks:

Black Ink; SW-9040 (PI:12418). White Ink; TekPrint SB-0007P White Ink (PI 2216).

6.2 INCOMPATIBILITIES

Not applicable.

6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below 25°C.

6.5 NATURE AND CONTENTS OF CONTAINER

Aclar/PVC/aluminium foil perforated unit dose blisters in cartons of 28, 56, and 84 capsules.


6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 PHYSICOCHEMICAL PROPERTIES

Chemical structure

The chemical name for niraparib tosilate monohydrate is (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl]phenyl}piperidinium 4-methylbenzenesulfonate monohydrate. The molecular formula is $C_{19}H_{20}N_4 \cdot OC_7H_8O_3S \cdot H_2O$ which corresponds to a formula weight of 510.61 g/mol. Niraparib tosilate monohydrate has one chiral centre of the S configuration. The chemical structure is shown below:



Niraparib tosilate monohydrate is a white to pale brown powder.

CAS number

1038915-60-4 (niraparib)

1613220-15-7 (niraparib tosilate monohydrate)

7 MEDICINE SCHEDULE (POISONS STANDARD)

Prescription Only Medicine (Schedule 4)

8 SPONSOR

GlaxoSmithKline Australia Pty Ltd
Level 4, 436 Johnston Street,
Abbotsford, Victoria, 3067

9 DATE OF FIRST APPROVAL

28 June 2019

10 DATE OF REVISION

22 November 2021

Summary table of changes

Section changed	Summary of new information
4.1	Additional indication

4.2	Posology based on body weight and platelet count
4.4	Hypertension section Additional adverse events based on the PRIMA clinical trial data
4.8	Photosensitivity added and addition of post marketing table
5.1	Addition of PRIMA clinical trial data
8	Sponsor address update

Version 3.0

Trade marks are owned by or licensed to the GSK group of companies.

© 2021 GSK group of companies or its licensor.